UNIGE document Scientific Article
previous document  unige:20735  next document
add to browser collection

Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN study

Ammann, Roland A.
Bodmer, Nicole
Hirt, Andreas
Niggli, Felix K.
Nadal, David
Simon, Arne
Kontny, Udo
show hidden authors show all authors [1 - 12]
Published in Journal of Clinical Oncology. 2010, vol. 28, no. 12, p. 2008-2014
Abstract PURPOSE To develop a score predicting the risk of adverse events (AEs) in pediatric patients with cancer who experience fever and neutropenia (FN) and to evaluate its performance. PATIENTS AND METHODS Pediatric patients with cancer presenting with FN induced by nonmyeloablative chemotherapy were observed in a prospective multicenter study. A score predicting the risk of future AEs (ie, serious medical complication, microbiologically defined infection, radiologically confirmed pneumonia) was developed from a multivariate mixed logistic regression model. Its cross-validated predictive performance was compared with that of published risk prediction rules. Results An AE was reported in 122 (29%) of 423 FN episodes. In 57 episodes (13%), the first AE was known only after reassessment after 8 to 24 hours of inpatient management. Predicting AE at reassessment was better than prediction at presentation with FN. A differential leukocyte count did not increase the predictive performance. The score predicting future AE in 358 episodes without known AE at reassessment used the following four variables: preceding chemotherapy more intensive than acute lymphoblastic leukemia maintenance (weight = 4), hemoglobin ≥ 90 g/L (weight = 5), leukocyte count less than 0.3 G/L (weight = 3), and platelet count less than 50 G/L (weight = 3). A score (sum of weights) ≥ 9 predicted future AEs. The cross-validated performance of this score exceeded the performance of published risk prediction rules. At an overall sensitivity of 92%, 35% of the episodes were classified as low risk, with a specificity of 45% and a negative predictive value of 93%. CONCLUSION This score, based on four routinely accessible characteristics, accurately identifies pediatric patients with cancer with FN at risk for AEs after reassessment.
Keywords Antineoplastic Agents/*adverse effectsChildChild, PreschoolFemaleFever/blood/*chemically induced/complications/*diagnosisGermanyHemoglobins/metabolismHumansLeukocyte CountLogistic ModelsMaleNeutropenia/blood/*chemically induced/complications/*diagnosisPlatelet CountPredictive Value of TestsPrognosisProspective StudiesReproducibility of ResultsRisk AssessmentRisk FactorsSensitivity and SpecificitySeverity of Illness IndexSwitzerland
PMID: 20231680
Full text
Article - document accessible for UNIGE members only Limited access to UNIGE
Other version: http://jco.ascopubs.org/content/28/12/2008.full.pdf
Research group Groupe Ozsahin Ayse Hulya (onco-hémato pédiatrie) (889)
(ISO format)
AMMANN, Roland A. et al. Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN study. In: Journal of Clinical Oncology, 2010, vol. 28, n° 12, p. 2008-2014. doi: 10.1200/JCO.2009.25.8988 https://archive-ouverte.unige.ch/unige:20735

457 hits

0 download


Deposited on : 2012-05-23

Export document
Format :
Citation style :